SERRAFLAZYME

Description

SERRAFLAZYME

5 mg (11,700 IU SP activity) ~ 100 Tablet

SERRAFLAZYME Serrapeptase anti-inflammatory, breaks interfascial and fascia to bone osteum scar adhesions, opens blocked arteries and veins, opens blocked lymphatic channels, reduces pericardia heart restriction, improves range of motion of joints, and reduces pain throughout the body.

● Anti-inflammatory, proteolytic, fibrinolytic, mucolytic, anti-edemic activity
● Potent mucolytic effect in glue ear, chronic bronchitis, sinusitis, otitis media and rhinopharyngitis
● Direct anti-inflammatory effects in post-traumatic swelling
● Repression of edema and blood vessel permeability
● Inhibits platelet aggregation
● Potentiates the effects of antibiotics in the treatment of infection

Common Uses: Serratia peptidase 5 mg – Used to help break down clots and vascular obstructions due to old venous thombosis, and recanalize blood vessels. Contains 5 mg of the purified food enzyme Serratia peptidase in an enterically-coated tablet. Designed for maximum absorption. May be used as an anti-inflammatory.

Instructions/How to Use: Suggested Use: 1 to 4 tablets daily before meals.

Ingredients: Description: Ingredients: Serrapeptase 5 mg. Equivalant to 10,000 iu activity This is a purified enzyme, serratia peptidase in an enterically coated tablet. It is scientifically designed for maximal absorption. This is a proteolytic enzyme isolated from the micro-organism, serratia E15, naturally present in silk worm intestines.

Cautions/Warnings: These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, or prevent any disease.

Esch PM, et al. Reduction of postoperative swelling. Objective measurement of swelling of the upper ankle joint in treatment with serrapeptase– a prospective study. Fortschr Med. 1989 Feb 10;107(4):67-8, 71-2.

Mazzone A, et al. Evaluation of Serratia peptidase in acute or chronic inflammation of otorhinolaryngology pathology: a multicentre, double-blind, randomized trial versus placebo. J Int Med Res. 1990 Sep-Oct;18(5):379-88.

Nakamura S, et al. Effect of the proteolytic enzyme serrapeptase in patients with chronic airway disease. Respirology. 2003 Sep;8(3):316-20.

Panagariya A, Sharma AK. A preliminary trial of serratiopeptidase in patients with carpal tunnel syndrome. J Assoc Physicians India. 1999 Dec;47(12):1170-2.

Selan L, et al. Proteolytic enzymes: a new treatment strategy for prosthetic infections? Antimicrob Agents Chemother. 1993 Dec;37(12):2618-21.